Learn more about the Agency's resources to support medicine development:

Learn more about how EMA interacts with academia.

Featured information for academics and researchers

EU agencies promoting a One Health approach

EMA and other scientific EU agencies responsible for human, animal health and environmental protection have established a task force to coordinate activities and share information, promoting a joined-up One Health approach. A paper is available containing more details.

New online platform for PRIME eligibility requests

As of 10 July 2023, medicine developers should use EMA’s IRIS platform to submit a PRIME eligibility request. Guidance is available on how to register for IRIS and use it for PRIME eligibility requests and other procedures

Bacteriophages as veterinary medicines: guideline now available

A CVMP guideline is available on the quality, safety and efficacy of bacteriophages as veterinary medicines. These viruses that infect bacteria could substitute or complement the use of antibiotics in animals. The guideline sets out the regulatory and scientific requirements for veterinary medicines designed for phage therapy and composed of bacteriophages

EMA communication activities

We asked stakeholders for feedback on our communication activities in a survey in 2022 and captured the results in a newly-published report. The findings help us set targets, address areas for improvement and measure progress. For example, we are already adapting our messaging to better suit audience needs and are creating more visuals based on survey insights. We thank all respondents for their feedback.

Engaging with academia: action plan for 2021 to 2023

EMA's academia collaboration matrix action plan sets out how EMA intends to create closer ties with academics and researchers in the next two and a half years. It lists actions in five areas: regulatory science and partnerships, innovation and support to academia, communication, events strategy, and training.

European medicines agencies network strategy to 2025

The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.

Latest news

EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease that causes muscles to become weak and leads to paralysis. Qalsody (tofersen) is indicated for the treatment of adults with ALS, who have a...

NewsHumanMedicines
SEE ALL NEWS

Upcoming events

The Clinical Trials Information System (CTIS) was launched on 31 January 2022, starting the clock for the three-year transition period from the Clinical Trials Directive to the Clinical Trials Regulation.

EventHumanClinical trials
SEE ALL EVENTS

Publications of interest

EMA's 2022 annual report

Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2022. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.

EMA’s individual stakeholder database: patients, consumers, healthcare professionals and academia - Frequently asked questions

How useful do you find this page?

Average: